Last reviewed · How we verify
DHEA treatment
DHEA (dehydroepiandrosterone) is an endogenous steroid hormone precursor that acts as a substrate for the synthesis of androgens and estrogens, modulating hormonal balance and immune function.
DHEA (dehydroepiandrosterone) is an endogenous steroid hormone precursor that acts as a substrate for the synthesis of androgens and estrogens, modulating hormonal balance and immune function. Used for Age-related DHEA deficiency, Systemic lupus erythematosus (SLE).
At a glance
| Generic name | DHEA treatment |
|---|---|
| Sponsor | University Hospital, Bordeaux |
| Drug class | Steroid hormone / Hormone replacement |
| Target | Androgen receptor, Estrogen receptor (indirect via metabolite conversion) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Aging / Immunology |
| Phase | Phase 3 |
Mechanism of action
DHEA is a naturally occurring C19 steroid produced by the adrenal glands and gonads. It serves as a precursor for testosterone and estrogen synthesis and is thought to enhance immune function, reduce inflammation, and improve metabolic parameters. The therapeutic rationale involves restoring age-related declines in DHEA levels to improve various physiological functions.
Approved indications
- Age-related DHEA deficiency
- Systemic lupus erythematosus (SLE)
Common side effects
- Acne
- Hirsutism
- Androgenic effects
- Headache
- Insomnia
Key clinical trials
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer (PHASE2)
- Neurobiological Mechanisms of Stress in Youth With Chronic Widespread Pain (NA)
- Effects of DHEA in Pulmonary Hypertension (PHASE2)
- The Effects of Fluoxetine and/or DHEA (EARLY_PHASE1)
- GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy. (PHASE4)
- Evaluate Pharmacokinetics and Safety of Slow Release DHEA (PHASE1, PHASE2)
- Vaginal Ecosystem and Network in the United States Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DHEA treatment CI brief — competitive landscape report
- DHEA treatment updates RSS · CI watch RSS
- University Hospital, Bordeaux portfolio CI